Navigation Links
Lexicon to Report Fourth Quarter and Year End 2010 Financial Results on February 24, 2011
Date:2/15/2011

THE WOODLANDS, Texas, Feb. 15, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, will release its fourth quarter and year end 2010 financial results on Thursday, February 24, 2011 before the financial markets open.  Lexicon management will hold a conference call and webcast to discuss clinical development progress and financial results for fourth quarter and year end 2010 at 11:00 a.m. Eastern Time on February 24, 2011.  

The dial-in number for the conference call is 888-220-1244 (within the US/Canada) or 706-679-5615 (international).  The conference ID for all callers is 44537933.  Investors can access a live webcast of the call at www.lexpharma.com.  An archived version of the webcast will be available on the website through March 24, 2011.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
2. Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
3. Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
4. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
5. Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
6. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2010 Financial Results
7. Lexicon Pharmaceuticals Announces Reacquisition of All Rights to Symphony Icon Programs
8. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
9. Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
10. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2010 Financial Results
11. Lexicon to Present at BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... COLUMBUS, Ohio , Feb. 8, 2016 /PRNewswire/ ... to introduce the PW Series Solvent Recycling Systems, ... series offers full integration with new and existing ... This integration produces consistently-fresh solvent through continuous recycling ... --> --> ...
(Date:2/8/2016)... , Feb. 8, 2016  Ventana Medical Systems, ... hundreds of the world,s top oncologists, pathologists, research ... the 12 th annual Tucson Symposium March ... theories and new outcomes in cancer research and ... lives. Thomas Grogan , annually draws ...
(Date:2/8/2016)... --  GS1 US will hold a series of ... Standards implementation to address the requirements of the U.S. ... rule. Scott Brown , director of ... director industry development, medical devices, GS1 US; and ... --> Scott Brown , director of ...
Breaking Medicine Technology:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Coast Dental ... February is National Children’s Dental Health Month and family dentist Yvonne Dorrian, DMD, is ... at Coast Dental , located next to Target at 1207 North Peachtree Parkway ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... BantamPro L top-load case packer for pouches, bags, and flow wrapped products at ... help co-packers and specialty product manufacturers step up to semi-automatic or fully-automatic case ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... metro area, has selected the latest beneficiary of their ongoing community enrichment program. ... preventing bullying in area schools. Donations are now being accepted at: http://www.angelsanddoves.com/donate.html ...
(Date:2/8/2016)... ... ... Remember the old saying “rub some dirt on it”? Perhaps you should ... Bentonite Clay” the health benefits of integrating clay into a daily diet are numerous, ... former motivational speaker, Perry A~ has since dedicated her life to learning about the ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... greater than 50% lower incidence rate of type 2 diabetes in the GrassrootsHealth ... ”It is time to make a change in public health,” states Carole Baggerly, ...
Breaking Medicine News(10 mins):